Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker NVCR · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC NCT06216301 · Metastatic Non-small Cell Lung Cancer NovoTTF-200T, Pembrolizumab | NVCR NovoCure GmbH | Phase 3 | Recruiting | 734 | Oct 2028 | Registry ↗ |
| Nov 6, 2026 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newl… NCT06556563 · Glioblastoma Optune® device, Temozolomide | NVCR NovoCure GmbH | Phase 3 | Active, not recruiting was recruiting | 741 | Apr 2029 | Registry ↗ |
| Oct 5, 2026 | Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ… NCT04471844 · Glioblastoma Multiforme Optune® | NVCR NovoCure Ltd. | Not applicable | Completed | 981 | Feb 19, 2026 | Registry ↗ |
| Sep 4, 2026 | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-P… NCT06390059 · Metastatic Pancreatic Ductal Adenocarcinoma Tumor Treating Fields, Atezolizumab | NVCR NovoCure Ltd. | Phase 2 | Completed | 84 | Nov 18, 2025 | Registry ↗ |
| Jun 1, 2026 | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Tre… NCT06558799 · Non-Small Cell Lung Cancer (NSCLC) NovoTTF-200T, Pembrolizumab | NVCR NovoCure GmbH | Phase 2 | Terminated | 31 | Feb 23, 2026 | Registry ↗ |
| Mar 18, 2026 | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for… NCT02973789 · Nonsmall Cell Lung Cancer, NSCLC NovoTTF-200T, Immune checkpoint inhibitors or docetaxel | NVCR NovoCure GmbH | Phase 3 | Completed | 291 | Sep 24, 2024 | Registry ↗ |
| Jan 21, 2026 | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pan… NCT03377491 · Pancreas Adenocarcinoma NovoTTF-200T, Gemcitabine | NVCR NovoCure Ltd. | Phase 3 | Completed | 571 | Oct 16, 2024 | Registry ↗ |
| Jan 6, 2026 | Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine a… NCT07319910 · Locally Advanced Pancreatic Adenocarcinoma TTFields, Gemcitabine | NVCR NovoCure GmbH | — | Temporarily not available | — | — | Registry ↗ |
| Oct 31, 2025 | Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFiel… NCT02831959 · Brain Metastases From Non-small Cell Lung Cancer (NSCLC) NovoTTF-200M device, Best Standard of Care | NVCR NovoCure GmbH | Phase 3 | Completed | 298 | Nov 29, 2024 | Registry ↗ |
| Aug 22, 2025 | TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study NCT05538806 · Pleural Mesothelioma TTFields | NVCR NovoCure Ltd. | — | Recruiting | 198 | Dec 2027 | Registry ↗ |
| Apr 23, 2025 | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kH… NCT04892472 · Non-small Cell Lung Cancer NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg | NVCR NovoCure GmbH | Phase 2 | Terminated | 15 | Jan 10, 2025 | Registry ↗ |
| Apr 11, 2025 | TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional S… NCT06924099 · Glioblastoma | NVCR NovoCure Ltd. | — | Recruiting | 430 | Jan 31, 2029 | Registry ↗ |
| Nov 14, 2024 | Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Tre… NCT04281576 · Gastric Cancer, GastroEsophageal Cancer NovoTTF-100L(P), Oxaliplatin | NVCR NovoCure Ltd. | Not applicable | Completed | 28 | Jun 7, 2024 | Registry ↗ |
| Nov 14, 2024 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatoce… NCT03606590 · Hepatocellular Carcinoma NovoTTF-100L(P) device, Sorafenib | NVCR NovoCure Ltd. | Phase 2 | Completed | 25 | Jan 14, 2021 | Registry ↗ |
| Aug 16, 2024 | Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurren… NCT04492163 · Glioblastoma Multiforme TTFields | NVCR NovoCure GmbH | Phase 2 | Completed | 25 | Jun 20, 2023 | Registry ↗ |
| Mar 29, 2024 | Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Trea… NCT03940196 · Ovarian Cancer NovoTTF-100L(O), Paclitaxel | NVCR NovoCure Ltd. | Phase 3 | Completed | 540 | May 18, 2023 | Registry ↗ |
| Jan 10, 2023 | TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study NCT04717739 · Glioblastoma TTFields | NVCR NovoCure Ltd. | — | Unknown | 500 | Dec 1, 2024 | Registry ↗ |
| Jul 7, 2021 | Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the… NCT04953234 · COVID-19 NovoTTF-100L | NVCR NovoCure GmbH | Not applicable | Completed | 10 | Apr 26, 2021 | Registry ↗ |
| Jan 28, 2021 | TTFields In GErmany in Routine Clinical Care NCT03258021 · Glioblastoma TTFields | NVCR NovoCure Ltd. | — | Unknown | 710 | Jun 2021 | Registry ↗ |
| Dec 20, 2018 | TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM NCT03780569 · Glioblastoma Multiforme NovoTTF-200A, Radiotherapy | NVCR NovoCure Ltd. | Not applicable | Unknown | 10 | Jan 2019 | Registry ↗ |
| Sep 25, 2018 | Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin… NCT02397928 · Malignant Pleural Mesothelioma NovoTTF-100L device, Pemetrexed | NVCR NovoCure Ltd. | Phase 2 | Completed | 82 | Apr 2018 | Registry ↗ |
| Sep 13, 2017 | Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant Wit… NCT01971281 · Pancreatic Adenocarcinoma NovoTTF-100L, Gemcitabine | NVCR NovoCure Ltd. | Phase 1/2 | Unknown | 40 | Dec 2017 | Registry ↗ |
| Apr 10, 2017 | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) NCT00916409 · Glioblastoma Multiforme NovoTTF-100A device, Temozolomide | NVCR NovoCure Ltd. | Phase 3 | Completed | 700 | Dec 2016 | Registry ↗ |
| Sep 21, 2016 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurren… NCT02244502 · Ovarian Carcinoma NovoTTF-100L(O), Paclitaxel | NVCR NovoCure Ltd. | Phase 1/2 | Unknown | 31 | Dec 2016 | Registry ↗ |
| Sep 21, 2016 | Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastase… NCT01755624 · 1-5 Brain Metastases From Non-Small Cell Lung Cancer NovoTTF-100A device, Best Standard of Care | NVCR NovoCure Ltd. | Phase 2 | Unknown | 18 | Jul 2017 | Registry ↗ |
| Mar 2, 2016 | Post-approval Study of NovoTTF-100A in Recurrent GBM Patients NCT01756729 · Recurrent Glioblastoma Multiforme NovoTTF-100A | NVCR NovoCure Ltd. | Phase 4 | Terminated | 13 | Jan 2018 | Registry ↗ |
26 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:45 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances